Cargando…

Review article: Follow‐up of coeliac disease

Coeliac disease is a lifelong immune‐mediated enteropathy with systemic features associated with increased morbidity and modestly increased mortality. Treatment with a strict gluten‐free diet improves symptoms and mucosal damage but is not curative and low‐level gluten intake is common despite stric...

Descripción completa

Detalles Bibliográficos
Autor principal: Tye‐Din, J. A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9542881/
https://www.ncbi.nlm.nih.gov/pubmed/35815829
http://dx.doi.org/10.1111/apt.16847
_version_ 1784804250966032384
author Tye‐Din, J. A.
author_facet Tye‐Din, J. A.
author_sort Tye‐Din, J. A.
collection PubMed
description Coeliac disease is a lifelong immune‐mediated enteropathy with systemic features associated with increased morbidity and modestly increased mortality. Treatment with a strict gluten‐free diet improves symptoms and mucosal damage but is not curative and low‐level gluten intake is common despite strict attempts at adherence. Regular follow‐up after diagnosis is considered best‐practice however this is executed poorly in the community with the problem compounded by the paucity of data informing optimal approaches. The aim of dietary treatment is to resolve symptoms, reduce complication risk and improve quality of life. It follows that the goals of monitoring are to assess dietary adherence, monitor disease activity, assess symptoms and screen for complications. Mucosal disease remission is regarded a key measure of treatment success as healing is associated with positive health outcomes. However, persistent villous atrophy is common, even after many years of a gluten‐free diet. As the clinical significance of asymptomatic enteropathy is uncertain the role for routine follow‐up biopsies remains contentious. Symptomatic non‐responsive coeliac disease is common and with systematic follow‐up a cause is usually found. Effective models of care involving the gastroenterologist, dietitian and primary care doctor will improve the consistency of long‐term management and likely translate into better patient outcomes. Identifying suitable treatment targets linked to long‐term health is an important goal.
format Online
Article
Text
id pubmed-9542881
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-95428812022-10-14 Review article: Follow‐up of coeliac disease Tye‐Din, J. A. Aliment Pharmacol Ther Publication of this special issue was made possible by Takeda Pharmaceuticals Coeliac disease is a lifelong immune‐mediated enteropathy with systemic features associated with increased morbidity and modestly increased mortality. Treatment with a strict gluten‐free diet improves symptoms and mucosal damage but is not curative and low‐level gluten intake is common despite strict attempts at adherence. Regular follow‐up after diagnosis is considered best‐practice however this is executed poorly in the community with the problem compounded by the paucity of data informing optimal approaches. The aim of dietary treatment is to resolve symptoms, reduce complication risk and improve quality of life. It follows that the goals of monitoring are to assess dietary adherence, monitor disease activity, assess symptoms and screen for complications. Mucosal disease remission is regarded a key measure of treatment success as healing is associated with positive health outcomes. However, persistent villous atrophy is common, even after many years of a gluten‐free diet. As the clinical significance of asymptomatic enteropathy is uncertain the role for routine follow‐up biopsies remains contentious. Symptomatic non‐responsive coeliac disease is common and with systematic follow‐up a cause is usually found. Effective models of care involving the gastroenterologist, dietitian and primary care doctor will improve the consistency of long‐term management and likely translate into better patient outcomes. Identifying suitable treatment targets linked to long‐term health is an important goal. John Wiley and Sons Inc. 2022-07-11 2022-07 /pmc/articles/PMC9542881/ /pubmed/35815829 http://dx.doi.org/10.1111/apt.16847 Text en © 2022 The Author. Alimentary Pharmacology & Therapeutics published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Publication of this special issue was made possible by Takeda Pharmaceuticals
Tye‐Din, J. A.
Review article: Follow‐up of coeliac disease
title Review article: Follow‐up of coeliac disease
title_full Review article: Follow‐up of coeliac disease
title_fullStr Review article: Follow‐up of coeliac disease
title_full_unstemmed Review article: Follow‐up of coeliac disease
title_short Review article: Follow‐up of coeliac disease
title_sort review article: follow‐up of coeliac disease
topic Publication of this special issue was made possible by Takeda Pharmaceuticals
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9542881/
https://www.ncbi.nlm.nih.gov/pubmed/35815829
http://dx.doi.org/10.1111/apt.16847
work_keys_str_mv AT tyedinja reviewarticlefollowupofcoeliacdisease